Literature DB >> 29878481

A review of factors associated with maintenance of sinus rhythm after elective electrical cardioversion for atrial fibrillation.

Veronika Ecker1, Charles Knoery2, Gordon Rushworth2,3, Ian Rudd2, Astrid Ortner1, David Begley4, Stephen J Leslie2,5.   

Abstract

Atrial fibrillation is the most common heart-rhythm disorder, affecting about 1.5% to 2% of the population with an increased risk of mortality and morbidity due to stroke, thromboembolism, and heart failure. If the conversion back to sinus rhythm does not happen spontaneously, pharmacological or electrical cardioversion (ECV) is the next available treatment options for some patients. However, the long-term success following ECV is variable. This review describes the factors that are associated with maintenance of sinus rhythm following ECV and proposes a clinical strategy based on the available evidence.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  Atrial Fibrillation; Electrical Cardioversion; Sinus Rhythm

Mesh:

Substances:

Year:  2018        PMID: 29878481      PMCID: PMC6489932          DOI: 10.1002/clc.22931

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  45 in total

1.  Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study.

Authors:  E Bertaglia; D D'Este; F Zerbo; F Zoppo; P Delise; P Pascotto
Journal:  Eur Heart J       Date:  2002-10       Impact factor: 29.983

2.  Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links.

Authors:  Gregory Y H Lip; George I Varughese
Journal:  Int J Cardiol       Date:  2005-12-07       Impact factor: 4.164

3.  Electrical cardioversion for atrial fibrillation: outcomes in "real-life" clinical practice.

Authors:  C Berry; S Stewart; E M Payne; J D McArthur; J J McMurray
Journal:  Int J Cardiol       Date:  2001-11       Impact factor: 4.164

4.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.

Authors:  A S Go; E M Hylek; K A Phillips; Y Chang; L E Henault; J V Selby; D E Singer
Journal:  JAMA       Date:  2001-05-09       Impact factor: 56.272

5.  Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation.

Authors:  M Frick; V Frykman; M Jensen-Urstad; J Ostergren; M Rosenqvist
Journal:  Clin Cardiol       Date:  2001-03       Impact factor: 2.882

Review 6.  Hyperthyroidism and the management of atrial fibrillation.

Authors:  Taeko Shimizu; Saori Koide; Jaduk Yoshimura Noh; Kiminori Sugino; Kohichi Ito; Hiroe Nakazawa
Journal:  Thyroid       Date:  2002-06       Impact factor: 6.568

7.  Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation.

Authors:  Hirotsugu Atarashi; Hiroshi Inoue; Masatake Fukunami; Kaoru Sugi; Chikuma Hamada; Hideki Origasa
Journal:  Circ J       Date:  2002-06       Impact factor: 2.993

8.  Obstructive sleep apnea and the recurrence of atrial fibrillation.

Authors:  Ravi Kanagala; Narayana S Murali; Paul A Friedman; Naser M Ammash; Bernard J Gersh; Karla V Ballman; Abu S M Shamsuzzaman; Virend K Somers
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

9.  Beta-blockers prevent subacute recurrences of persistent atrial fibrillation only in patients with hypertension.

Authors:  Trudeke Van Noord; Robert G Tieleman; Hans A Bosker; Tsjerk Kingma; Dirk J Van Veldhuisen; Harry J G M Crijns; Isabelle C Van Gelder
Journal:  Europace       Date:  2004-07       Impact factor: 5.214

10.  VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study).

Authors:  Antonio De Simone; Michele De Pasquale; Carmine De Matteis; Michelangelo Canciello; Michele Manzo; Luigi Sabino; Ferdinando Alfano; Michele Di Mauro; Andrea Campana; Giuseppe De Fabrizio; Dino Franco Vitale; Pietro Turco; Giuseppe Stabile
Journal:  Eur Heart J       Date:  2003-08       Impact factor: 29.983

View more
  8 in total

Review 1.  [2020 ESC guidelines on atrial fibrillation : Summary of the most relevant recommendations and innovations].

Authors:  Alireza Sepehri Shamloo; Nikolaos Dagres; Gerhard Hindricks
Journal:  Herz       Date:  2021-02       Impact factor: 1.443

2.  Role for machine learning in sex-specific prediction of successful electrical cardioversion in atrial fibrillation?

Authors:  Nicklas Vinter; Anne Sofie Frederiksen; Andi Eie Albertsen; Gregory Y H Lip; Morten Fenger-Grøn; Ludovic Trinquart; Lars Frost; Dorthe Svenstrup Møller
Journal:  Open Heart       Date:  2020-06

3.  Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) randomized trial.

Authors:  Gregory Y H Lip; Jose L Merino; Maciej Banach; Naab Al-Saady; James Jin; Michael Melino; Shannon M Winters; Monika Kozieł; Andreas Goette
Journal:  J Arrhythm       Date:  2020-04-15

4.  Catheter ablation of atrial fibrillation after pericardiectomy: multi-center experience in China.

Authors:  Ronghui Yu; Hui Xi; Peize Wang; Dongling Xu; Jun Lu; Fengqiang Xu; Lei An; Xin Zhao; Rong Bai
Journal:  Ann Transl Med       Date:  2020-05

Review 5.  Mid-Diastolic Events (L Events): A Critical Review.

Authors:  Emanuele Di Virgilio; Francesco Monitillo; Daniela Santoro; Silvia D'Alessandro; Marco Guglielmo; Andrea Baggiano; Laura Fusini; Riccardo Memeo; Mark G Rabbat; Stefano Favale; Matteo Cameli; Andrea Igoren Guaricci; Gianluca Pontone
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

6.  Circular RNA mmu_circ_0005019 inhibits fibrosis of cardiac fibroblasts and reverses electrical remodeling of cardiomyocytes.

Authors:  Na Wu; Chengying Li; Li Zhong; Yafei Li; Bin Xu; Ying Xiang; Xiaoyue Jia; Zhiquan Yuan; Long Wu
Journal:  BMC Cardiovasc Disord       Date:  2021-06-21       Impact factor: 2.298

7.  Efficacy and Safety of Outpatient Clinic-based Elective External Electrical Cardioversion in Patients with Atrial Fibrillation.

Authors:  Nguyen Khac Le Son; Je Wook Park; Min Kim; Song Yi Yang; Hee Tae Yu; Tae Hoon Kim; Jae Sun Uhm; Boyoung Joung; Moon Hyoung Lee; Hui Nam Pak
Journal:  Korean Circ J       Date:  2020-03-12       Impact factor: 3.243

8.  The efficacy and safety of amiodarone combined with beta-blockers in the maintenance of sinus rhythm for atrial fibrillation: A protocol for systematic review and network meta-analysis.

Authors:  Shuqing Shi; Qiulei Jia; Jingjing Shi; Shuai Shi; Guozhen Yuan; Yuanhui Hu
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.